SI-BONE Posts Record 2025 Results and Strong 2026 Outlook

An update from SI-Bone ( (SIBN) ) is now available.

On February 20, 2026, SI-BONE signed a long-term lease for roughly 50,485 square feet of space in San Jose, California, securing expansion capacity with tenant incentives that include six months of rent abatement and substantial improvement and power-upgrade allowances, and it also gained an option on adjacent space that could further increase its footprint. On February 22, 2026, the company expanded the remit of Chief Financial Officer Anshul Maheshwari to include Chief Operating Officer, and on February 23, 2026 it reported record 2025 results with worldwide revenue up 20.2% to $200.9 million, improved margins, positive adjusted EBITDA and free cash flow in the fourth quarter, alongside 2026 guidance calling for mid-teens revenue growth and higher profitability that underscores strengthening operating leverage and a more entrenched position in its niche orthopedic market.

The most recent analyst rating on (SIBN) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on SI-Bone stock, see the SIBN Stock Forecast page.

Spark’s Take on SIBN Stock

According to Spark, TipRanks’ AI Analyst, SIBN is a Neutral.

The score is held back primarily by weak underlying profitability and cash flow despite steady revenue growth and a stable balance sheet. Technicals are supportive with price above key moving averages and positive momentum, while valuation is challenged by a negative P/E and no dividend. Recent earnings commentary improves the outlook via raised guidance and improving EBITDA/cash flow milestones, but it is not yet enough to offset the still-loss-making financial profile.

To see Spark’s full report on SIBN stock, click here.

More about SI-Bone

SI-BONE, Inc. is a medical technology company and global leader in developing procedural solutions for clinical challenges associated with compromised bone, with a technology platform focused on the spinopelvic anatomy. The Nasdaq-listed group leverages biomechanical design and anatomy-specific innovation to support sacroiliac joint fusion and related procedures, and has backed more than 140,000 procedures worldwide since 2009 with a substantial clinical evidence base.

Average Trading Volume: 520,338

Technical Sentiment Signal: Sell

Current Market Cap: $683M

See more data about SIBN stock on TipRanks’ Stock Analysis page.